Bayer AG annual cash and equivalents
2020
2021
2022
2023
2024
2025
Bayer AG Cash & Equivalents Growth & History (BAYN)
Bayer AG's cash and equivalents was €6.67B for fiscal 2025.
View full Bayer AG company overviewBayer AG annual cash and equivalents history
| Fiscal year | Period ended | Cash and equivalents | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | €6.67B | €480.0M | +7.75% |
| 2024 | 2024-12-31 | €6.19B | €284.0M | +4.81% |
| 2023 | 2023-12-31 | €5.91B | €736.0M | +14.23% |
| 2022 | 2022-12-31 | €5.17B | €607.0M | +13.30% |
| 2021 | 2021-12-31 | €4.56B | €373.0M | +8.90% |
| 2020 | 2020-12-31 | €4.19B | — | — |
Bayer AG quarterly cash and equivalents
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Cash and equivalents | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | €4.29B | −€268.0M | −5.88% |
| Q1 2026 | 2026-03-31 | €5.73B | — | — |
| Q4 2025 | 2025-12-31 | €6.67B | — | — |
| Q3 2025 | 2025-09-30 | €5.90B | — | — |
| Q2 2025 | 2025-06-30 | €4.56B | — | — |
Bayer AG cash and equivalents trends
Over the last five fiscal years, Bayer AG's cash and equivalents increased from €4.19B to €6.67B, a change of €2.48B. The latest reported quarter, Q2 2026, shows €4.29B.
About the metric
What cash and equivalents mean
Cash and cash equivalents, often described as cash on hand, are highly liquid resources available for near-term obligations, investment, acquisitions, debt repayment, dividends, or share repurchases. This measure does not include short-term investments reported separately.
Calculation and source
Reported cash and equivalents
TickerStat standardizes cash and cash equivalents reported on the balance sheet. Restricted cash is included only when the company reports it within the selected consolidated cash concept. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Bayer AG source filings ↗Community posts
Bayer wins the first Roundup trial following the Supreme Court ruling
A Missouri jury unanimously ruled for Bayer ($BAYN)’s Monsanto unit in a three-plaintiff Roundup case, rejecting design-defect, fraud and negligence claims. It was the first such trial following the US Supreme Court decision that blocked th ...
Bayer’s Nubeqa cuts risk of metastasis or death in prostate trial
Bayer ($BAYN) disclosed interim Phase 3 results showing that adding Nubeqa to hormone therapy and radiation reduced the risk of metastasis or death by 58% in prostate-cancer patients at high risk of recurrence. Four-year metastasis-free sur ...
